Ownership and insider activity for Ainos, Inc. (AIMD): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Ainos, Inc. operates as a healthcare technology company, specializing in point-of-care diagnostics and the development of safe, novel treatments for various disease indications. Its current portfolio encompasses a COVID-19 antigen rapid test kit, which integrates with a cloud-based test management platform known as the Ainos App, offering both personal and enterprise applications.
Price
| Price | $1.38 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-06-05 | chiang yao-chung | P-Purchase | 3,500 | $7K |
| 2026-06-03 | chiang yao-chung | P-Purchase | 2,000 | $4K |
| 2026-05-28 | chiang yao-chung | P-Purchase | 250 | $575 |
| 2026-05-27 | chiang yao-chung | P-Purchase | 2,000 | $4K |
| 2026-05-26 | lee ting-chuan | S-Sale | 109,988 | $209K |
| 2026-05-26 | Taiwan Carbon Nano Technology Corp | S-Sale | 41,000 | $97K |
| 2026-05-22 | TSAI CHUN-JUNG | S-Sale | 1,082 | $2K |
| 2026-05-26 | TSAI CHUN-JUNG | S-Sale | 27,718 | $52K |
| 2026-05-21 | lee ting-chuan | S-Sale | 9,000 | $14K |
| 2026-05-22 | lee ting-chuan | S-Sale | 9,302 | $15K |
Balance Sheet (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $134125 | $2.0M | $1.3M | $409039 | $22245 | $1.8M | $1.9M | $1.9M | $3.9M | $417353 |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | -$32124 | 0 | 0 | $201546 | $455 | $56 | $22 |
| Inventory | $14700 | $22666 | 0 | $4131 | $3024 | 0 | $595222 | $167593 | $143756 | $295565 |
| Total Current Assets | $262399 | $2.1M | $1.3M | $445294 | $76413 | $2.2M | $2.8M | $2.5M | $4.3M | $1.1M |
| Property, Plant & Equipment | $44214 | $26997 | $14010 | $5069 | $3249 | $1.2M | $1.4M | $876572 | $559645 | $343281 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | $156063 | $182386 | $146456 | $146263 | $180628 | $37.3M | $32.8M | $28.3M | $23.7M | $19.2M |
| Total Assets | $462676 | $2.3M | $1.5M | $596626 | $260290 | $40.8M | $37.1M | $31.8M | $28.8M | $20.9M |
| Accounts Payable | $168761 | $159300 | $115313 | $208727 | $145567 | 0 | 0 | 0 | 0 | 0 |
| Short-term Debt | $791481 | $886481 | $513356 | $444581 | $953000 | $3.6M | $1.3M | $42000 | $3.0M | 0 |
| Total Current Liabilities | $1.3M | $1.8M | $733621 | $753308 | $1.1M | $30.6M | $2.5M | $1.3M | $4.0M | $1.1M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $5.9M | $9.0M | $11.0M |
| Total Liabilities | $1.3M | $1.8M | $733621 | $753308 | $1.1M | $30.6M | $2.5M | $7.4M | $13.3M | $13.3M |
| Retained Earnings | -$1.3M | -$1.9M | -$3.2M | -$4.8M | -$6.2M | -$10.1M | -$24.1M | -$37.9M | -$52.7M | -$67.5M |
| Total Equity | -$809899 | $470795 | $730079 | -$156682 | -$838278 | $10.2M | $34.6M | $24.4M | $15.5M | $7.6M |
| Total Debt | $791481 | $886481 | $513356 | $444581 | $953000 | $3.6M | $1.3M | $6.0M | $12.0M | $11.0M |
| Net Debt | $657356 | -$1.1M | -$763298 | $35542 | $930755 | $1.9M | -$584740 | $4.1M | $8.1M | $10.6M |
| Working Capital | -$1.0M | $261412 | $569613 | -$308014 | -$1.0M | -$28.4M | $373005 | $1.1M | $382864 | $60116 |
Financial Health
| Debt / Equity | 4.21 |
| Current Ratio | 0.13 |
Profitability
| Return on Equity | -217.50% |
| Return on Invested Capital | -80.51% |
| Return on Assets | -73.89% |
| Gross Margin | -34987.54% |
| Operating Margin | -101210.17% |
| Net Margin | -106283.32% |
Related companies: ADTX · ANL · ATHA · BLRX · DARE · FBLG · GOVX
Explore sector: Healthcare · Biotechnology
More sections of AIMD: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks